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Background/Aims: The aim of this study was to quantitatively measure changes in lipids and lipoproteins during
perimenopause and to identify variables related to these changes. 
Methods: Among women who had three regular health evaluations over a span of 2-4 years, 34 women remained
in the premenopausal state, 34 premenopausal women transitioned to the postmenopausal state, and 36 post-
menopausal women were enrolled. The menopausal state was determined not only by a history of amenorrhea
but also by levels of female sex hormones. Yearly changes in lipids were calculated using a linear regression of
the three measurements. 
Results: The transition from premenopause to postmenopause was associated with increased total cholesterol
and low-density lipoprotein (LDL) cholesterol levels by 7.4 ± 8.0 mg/dL (4.2 ± 4.9%) and 6.9 ± 6.5 mg/dL (6.8 ± 7.0
%) over one year, resulting in an elevation of 19.6 ± 22.6 mg/dL (10.9 ± 13.0%) and 18.9 ± 19.5 mg/dL (18.6 ±
20.3%), respectively, during perimenopause. There were no changes observed in premenopausal and post-
menopausal women. Body weight, blood pressure, high-density lipoprotein (HDL) cholesterol, and triglycerides did
not change in any of the three groups. In all women, changes in both total cholesterol and LDL cholesterol were
associated with changes in follicle stimulating hormone (r = 0.40, p < 0.001 and r = 0.38, p < 0.001, respectively).
Changes in triglycerides were associated with changes in body weight (r = 0.28, p = 0.005). 
Conclusions: During perimenopause, total and LDL cholesterol levels increase and these changes in cholesterol
are mainly dependent on changes in female sex hormones. (Korean J Intern Med 2011;26:47-53)
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INTRODUCTION
Premenopausal women have distinctly less atheroscle-
rotic cardiovascular diseases than men. After menopause,
this incidence steeply increases, resulting in no difference
between men and women in individuals older than 70.
Therefore, menopause is considered as one of the risk fac-
tors for atherosclerotic diseases [1].
Many studies have shown that total cholesterol and low-
density lipoprotein (LDL) cholesterol increase after
menopause [2-11]. However, it is controversial as to what
extent these atherogenic lipids are elevated. Cross-section-
al studies have shown a considerable influence [2-4],
whereas most longitudinal follow-up studies reveal only
small changes [5-11]. It is also unclear whether the transi-
tion from premenopause to postmenopause leads to a
decrease in high-density lipoprotein (HDL) cholesterol [7-
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Changes in female sex hormones precede the cessation
of menstruation [12]. Therefore, lipid profiles may start to
change before menopause [11]. Since nearly all studies
define postmenopausal status based on amenorrhea with-
out measurements of female sex hormones [7], it is possi-
ble that these changes have been underestimated. 
There are relatively few studies that have examined the
mechanisms underlying changes in lipid profiles during
the perimenopause. Many studies have observed the para-
meters affecting lipid levels [5-10,13]; however, the rela-
tionship of these variables with lipid levels was not evalu-
ated.
In this longitudinal follow-up study, we investigated
quantitative changes in lipid and lipoprotein profiles dur-
ing the transition from premenopause to postmenopause,
which were defined by both female sex hormones and
amenorrhea history, and the parameters related to these
changes.
METHODS
Women who had three regular health evaluations over
the course of 2-4 years between 1999 and 2007 were
screened. The regular health examination included the fol-
lowing: 1) history of medical illness, medication, and men-
struation, 2) height and weight, 3) laboratory tests includ-
ing complete blood count, urinalysis, routine blood chem-
istry, thyroid function tests, cancer markers, electrocar-
diogram, and chest X-ray, 4) ultrasound examination of
the abdomen, and 5) esophagogastroduodenal endoscopy. 
Among these women, 34 premenopausal women
remained in the premenopausal state (premenopausal
group), 34 premenopausal women transitioned to the
postmenopausal state (perimenopausal group), and 36
postmenopausal women (postmenopausal group) were
enrolled. The premenopausal state was defined as regular
menstruation and follicle stimulating hormone levels
(FSH) < 20 IU/L. The postmenopausal state was defined
as amenorrhea ≥ 6 months and FSH levels ≥ 20 IU/L.
Finally, the perimenopausal state was defined as the tran-
sition from premenopausal state to postmenopausal dur-
ing follow-up. 
Exclusion criteria included 1) diabetes mellitus, 2)
hepatitis with aspartate aminotransferase or alanine
aminotransferase levels ≥ 2-fold the upper normal limit,
3) other diseases that influence lipid levels such as infec-
tious diseases, and 4) medications that affect lipid levels
including female sex hormones and lipid lowering drugs
during the follow-up period. 
After overnight fasting, blood samples were obtained.
Total cholesterol and triglycerides were determined by the
enzymatic method using an automatic analyzer (Model
7150, Hitachi, Japan). HDL-C was measured by direct
methods using an automatic analyzer. LDL-C was calcu-
lated using the Friedewald formula. FSH and estradiol
were determined using radioimmunoassay (RIA) meth-
ods.
To minimize the biological variation in lipid levels, year-
ly changes in lipid levels were calculated from a linear
regression line of the three measurements against age.
Total change was obtained by multiplying yearly changes
by the duration of follow-up.
Data are expressed as the mean ± SD. Statistical analy-
ses were performed using SPSS version 9.0 (SPSS Inc.,
Chicago, IL, USA). An analysis of variance (ANOVA) or a
Kruskal-Wallis test was used to evaluate differences
among groups. The Friedman test was used to compare
serial changes. Relationships among variables were ana-
lyzed using the Pearson correlation method. A stepwise
linear regression method was used to identify indepen-
dent parameters. The distribution of discrete variables
was analyzed using a χ
2 test. A two-tailed p value < 0.05
was considered statistically significant.
Figure 1. Comparison of yearly changes in lipid profiles among
premenopausal women, perimenopausal women, and post-
menopausal women. Mean ± SE; ap < 0.05; LDL-C, low density
lipoprotein-cholesterol; HDL-C, high density lipoprotein-cho-
lesterol.Cho EJ, et al. Menopause, Iipids, and related parameters    49
RESULTS
The perimenopausal group was younger than the post-
menopausal group (p < 0.001) and older than the pre-
menopausal group (p < 0.001, Table 1). The younger pre-
menopausal group tended to be taller than the older post-
menopausal group (p = 0.093). Other social histories,
associated diseases, and the duration of the follow-up
period were not different among groups. 
The transition from premenopause to postmenopause
was associated with increased total cholesterol and LDL
cholesterol levels by 7.4 ± 8.0 mg/dL (4.2 ± 4.9%) and 6.9
± 6.5 mg/dL (6.8 ± 7.0%) over the course of one year (Fig.
1), resulting in a total elevation of 19.6 ± 22.6 mg/dL (10.9
± 13.0%) and 18.9 ± 19.5 mg/dL (18.6 ± 20.3%) during the
perimenopausal period, respectively (Table 2). Increases
in total cholesterol and LDL cholesterol levels were greater
in the perimenopausal group as compared with the pre-
menopausal group (-0.64 ± 24.4 mg/dL [0.23 ± 12.3%], p
= 0.002 and -0.74 ± 22.5 mg/dL [0.50 ± 18.2%], p <
0.001, respectively) and the postmenopausal group (5.17 ±
23.7 mg/dL [3.23 ± 11.6%], p = 0.009 and 6.29 ± 23.3
mg/dL [5.24 ± 25.5%], p = 0.007, respectively). Body
weight, blood pressure, HDL cholesterol, and triglycerides
did not differ in any of the three groups. 
In all women (n = 104), changes in total cholesterol
were positively associated with changes in FSH (r = 0.40,
p < 0.001) (Table 3, Fig. 2) and negatively with changes in
estradiol (r = -0.20, p = 0.046). In the multivariate analy-
sis, FSH was an independent variable. Changes in LDL
cholesterol were associated with changes in FSH (r =
0.38, p < 0.001), and this elevation was greater in women
with hypertension (r = 0.25, p = 0.010) than in women
without hypertension. An increase in triglycerides was
related to changes in body weight (r = 0.28, p = 0.005)
and was greater in women without hypertension (r = 0.19,
p = 0.049). In the multivariate analysis, body weight was
an independent variable.
In perimenopausal women (n = 34) (Table 4), changes
in both total cholesterol and LDL cholesterol were associ-
ated with changes in follicle stimulating hormone (r =
0.46, p = 0.006 and r = 0.35, p = 0.044, respectively).
Changes in triglycerides were negatively associated with
changes in estradiol (r= -0.47, 0.006). 
DISCUSSION
This retrospective cohort study demonstrates that the
transition from premenopause to postmenopause is asso-
ciated with an increase in total cholesterol and LDL cho-
Table 1. Comparison of baseline clinical characteristics among premenopausal women, perimenopausal women,
and postmenopausal women
Premenopause (n = 34) Perimenopause (n = 34) Postmenopause (n = 36) ANOVA
Age at the end of study, yr 47.9 ± 2.23 50.6 ± 3.24 55.6 ± 3.39 < 0.001
Height, cm 158.4 ± 5.14 157.0 ± 4.84 156.2 ± 3.97 0.093
Smoking 3 (8.8) 2 (5.9) 1 (1.8) 0.56
Alcohol 10 (29.4) 8 (23.5) 7 (19.4) 0.62
Exercise 7 (20.6) 11 (32.4) 11 (30.6) 0.81
Associated disease
Hypertension 5 (14.7) 4 (11.8) 7 (19.4) 0.67
Duration of follow-up, yr 2.8 ± 0.92 2.8 ± 1.11 2.4 ± 0.53 0.13
Values are presented as mean ± SD or number (%).
ANOVA, analysis of variance.
Figure 2. Relationship between changes in cholesterol levels
(yearly change × follow-up year) with changes in follicle stimu-
lating hormone (FSH) in all women.50 The Korean Journal of Internal Medicine Vol. 26, No. 1, March 2011
lesterol levels and no change in HDL cholesterol levels.
This elevation in atherogenic lipids was greater than those
reported in previous follow-up studies. In addition,
increases in total cholesterol and LDL cholesterol are
related not to changes in body weight or fasting blood
sugar, but mainly to changes in female sex hormones.
In the present study, changes in lipid levels were calcu-
lated using linear regression methods to minimize the
Table 2. Changes in clinical and lipid profiles in premenopausal women, perimenopausal women, and post-
menopausal women during the follow-up period
Premenopause (n = 34) Perimenopause (n = 34) Postmenopause (n = 36) ANOVA
Weight, kg 1st visit 57.0 ± 9.77 56.2 ± 5.68 57.1 ± 7.14 0.87
2nd visit 57.0 ± 8.33 56.4 ± 5.41 56.9 ± 6.88 0.92 
3rd visit 58.0 ± 9.14 56.0 ± 5.16 57.0 ± 6.84 0.51  
p value 0.13 0.40 0.25
SBP, mmHg 1st visit 114.2 ± 14.8 115.2 ± 17.4 113.3 ± 15.4 0.89
2nd visit 116.7 ± 16.9 116.3 ± 12.6 116.8 ± 14.6 0.99
3rd visit 118.9 ± 13.8 118.3 ± 17.0 117.6 ± 14.2 0.94
p value 0.67 0.25 0.80
DBP, mmHg 1st visit 73.5 ± 12.2 72.2 ± 12.7 72.2 ± 12.7 0.76
2nd visit 70.0 ± 10.0 71.4 ± 9.50 73.0 ± 10.4 0.47
3rd visit 71.1 ± 9.68 70.7 ± 10.8 72.7 ± 11.4 0.71
p value 0.06 0.055 0.56
TC, mg/dL 1st visit 193.6 ± 28.9 197.9 ± 32.7 203.0 ± 27.4 0.41
2nd visit 194.3 ± 31.8 203.8 ± 33.7 212.5 ± 30.9 0.064
3rd visit 193.0 ± 32.2 217.5 ± 32.4 207.6 ± 27.5 0.006
p value 0.68 0.007 0.40
LDL-C, mg/dL 1st visit 116.2 ± 22.9 118.7 ± 27.6 123.7 ± 27.3 0.47
2nd visit 115.9 ± 27.6 124.4 ± 30.8 134.1 ± 28.8 0.037
3rd visit 115.7 ± 28.0 137.9 ± 27.5 129.1 ± 25.4 0.004
p value 0.83 0.001 0.19
HDL-C, mg/dL 1st visit 58.0 ± 11.8 58.6 ± 10.9 58.2 ± 12.3 0.98
2nd visit 59.0 ± 13.1 58.7 ± 12.9 58.7 ± 12.5 0.99
3rd visit 57.4 ± 12.3 57.4 ± 13.2 57.7 ± 12.3 0.99
p value 0.70 0.70 0.63
TG, mg/dL 1st visit 96.5 ± 46.1 103.5 ± 61.4 105.4 ± 62.4 0.79
2nd visit 96.7 ± 44.6 103.8 ± 64.4 98.9 ± 40.8 0.84
3rd visit 99.4 ± 56.6 110.9 ± 66.0 103.8 ± 49.3 0.71
p value 0.77 0.76 0.82
FSH, IU/L 1st visit 6.20 ± 3.70 7.91 ± 5.19 72.8 ± 24.5 < 0.001
2nd visit 6.16 ± 4.52 20.6 ± 19.8 70.1 ± 23.9 < 0.001
3rd visit 7.56 ± 4.70 52.4 ± 24.7 67.5 ± 20.0 < 0.001
p value 0.09 0.002 0.067
E2, pg/mL 1st visit 89.2 ± 52.0 105.6 ± 68.3 12.4 ± 11.3 < 0.001
2nd visit 135.4 ± 135.5 127.4 ± 176.4 17.2 ± 12.2 < 0.001
3rd visit 169.0 ± 168.0 35.4 ± 38.7 14.1 ± 7.16 < 0.001
p value 0.06 0.054 0.085
FBS, mg/dL 1st visit 92.7 ± 8.03 91.8 ± 7.30 94.6 ± 10.1 0.38
2nd visit 94.1 ± 7.17 94.0 ± 7.89 96.4 ± 9.71 0.39
3rd visit 92.6 ± 7.04 96.6 ± 7.03 94.5 ± 11.7 0.20
p value 0.69 0.13 0.64
ANOVA, analysis of variance; SBP, systolic blood pressure; DBP, diastolic blood pressure; TC, total cholesterol; LDL-C, low density lipoprotein-
cholesterol; HDL-C, high density lipoprotein-cholesterol; TG, triglyceride; FSH, follicle stimulating hormone; E2, estradiol; FBS, fasting blood sugar.Cho EJ, et al. Menopause, Iipids, and related parameters    51
influence of biological and analytical variations in lipid
levels. However, changes in lipid levels calculated using
this method were similar to those obtained via direct
extraction of the first measurements from the last ones
with a difference of < 3% (p> 0.05, data not shown). 
Many studies have shown that total cholesterol and LDL
cholesterol increase after menopause. In cross-sectional
studies, total cholesterol was elevated by 9-19% and LDL
cholesterol by 10-24% [2-4,14]. However, in longitudinal
follow-up studies, total cholesterol was elevated by 5-
14.2% and LDL cholesterol by 3.5-16% over the course of
2-6 years [5-10]. When changes in the control group, usu-
ally premenopausal women, were considered (2.6-9.6%
for total cholesterol and 6.3-6.4% for LDL cholesterol),
increases in total cholesterol and LDL cholesterol were
only 2.4-7.2% and -2.9-9.7% respectively [5-10]. In the
present study, total cholesterol and LDL cholesterol were
elevated by 10.9% and 18.6%, respectively and changes in
premenopausal women were negligible during the 2.8
years. Therefore, increases in atherogenic lipids observed
in the present study were greater than those of previous
studies. In one study that did not have a control group,
total cholesterol and LDL cholesterol increased by 14%
and 19%, respectively, from 4 years before to 1 year after
menopause [11].
In almost all previous studies, menopausal status was
determined only by amenorrhea history. Changes in
female sex hormones precede the cessation of menstrua-
tion [12]. Women with regular menstruation and with
altered female sex hormone levels may be assigned to the
premenopausal state. However, atherogenic lipid levels
have already begun to increase and these women have
higher atherogenic lipid levels than premenopausal
women with normal female sex hormone levels [11].
Therefore, changes during perimenopause may be under-
estimated and those in women remaining in the pre-
menopausal state may be overestimated.
In addition, some women might be incorrectly catego-
rized into the postmenopausal state because of amenor-
rhea due to other causes, even though female sex hor-
mones are in the premenopausal state. In these women,
atherogenic lipids have not yet increased. Therefore, if
menopausal status is determined only by amenorrhea, it is
possible that changes during perimenopause are underes-
timated and changes in postmenopausal women are over-
estimated. In the present study, menopausal state was
determined not only amenorrhea history but also by
female sex hormones. This difference in the definition of
Table 3. Relationship between changes in lipid levels (yearly change × × follow-up year) with clinical and laboratory
parameters in all women (n = 104)
Changes in TC Changes in LDL-C Changes in HDL-C Changes in TG
Changes in weight -0.06 -0.14 -0.18 0.28a
Changes in FSH 0.40a 0.38a 0.02 0.09
Changes in E2 -0.20a -0.13 0.03 -0.19
Changes in FBS 0.16 0.09 0.11 0.09
Hypertension 0.18 0.25a 0.12 -0.19a
TC, total cholesterol; LDL-C, low density lipoprotein-cholesterol; HDL-C, high density lipoprotein-cholesterol; TG, triglyceride; FSH, follicle stimulat-
ing hormone; E2, estradiol; FBS, fasting blood sugar.
ap < 0.05.
Table 4. Relationship between changes in lipid levels (yearly change × × follow-up year) with clinical and laboratory
parameters in perimenopausal women (n = 34)
Changes in TC/yr × yr Changes in LDL-C/yr × yr Changes in HDL-C/yr × yr Changes in TG/yr × yr
Changes in weight -0.23 -0.30 -0.18 0.22
Changes in FSH 0.46a 0.35a 0.24 0.16
Changes in E2 -0.19 0.10 -0.18 -0.47a
Changes in FBS 0.28 0.14 0.26 0.15 
Hypertension 0.10 0.19 -0.04 -0.11
TC, total cholesterol; LDL-C, low density lipoprotein-cholesterol; HDL-C, high density lipoprotein-cholesterol; TG, triglyceride; FSH, follicle stimulat-
ing hormone; E2, estradiol; FBS, fasting blood sugar.
ap < 0.05.52 The Korean Journal of Internal Medicine Vol. 26, No. 1, March 2011
menopausal status might explain why the elevation in
atherogenic lipids was greater in the present study, as
compared with previous studies. 
In the present study, enrolled women had extensive lab-
oratory examinations and women with diseases affecting
lipid levels were excluded. In contrast, most previous fol-
low-up studies were dependent on interviews or question-
naires to evaluate health status. During the transition
from premenopause to postmenopause, considerable
numbers of women experience the onset of diseases
affecting lipid levels. This difference in evaluating health
status also partially explains the reason why the elevation
in atherogenic lipids is greater in the present study than in
previous studies.
It has been generally accepted that HDL cholesterol
decreases after menopause, without solid evidence. In
cross-sectional studies, changes in HDL cholesterol after
menopause were relatively variable [2-4,14]. In follow-up
studies, all studies, excluding a few, failed to demonstrate
the decrease in HDL cholesterol after menopause [7-11].
In studies examining the effects of surgical menopause,
HDL cholesterol did not decrease [15]. In the present
study, the transition from premenopause to post-
menopause was not associated with a decrease in HDL
cholesterol. Therefore, loss of female sex hormones alone
may not influence HDL cholesterol level.
To the best of our knowledge, there have been no
reports that have identified variables associated with
changes in lipid profiles during perimenopause. In almost
all previous studies, parameters related to lipid levels,
such as body weight or fasting blood sugar, did not change
after menopause [5-10,13,16]. In the present study, these
parameters were also unchanged. Changes in total choles-
terol and LDL cholesterol were independently related to
changes in FSH in both perimenopausal women and all
women combined. These findings suggest that changes in
total cholesterol and LDL cholesterol associated with
menopause are mainly dependent on female sex hor-
mones. Although changes in estradiol were also related to
changes in lipid levels, this difference was not significant
in the multivariate analysis. We believe that large biologi-
cal variation may weaken the statistical power. 
In all groups, LDL cholesterol increased more in women
with hypertension than in women without hypertension (r
= 0.25, p = 0.010). This phenomenon was independent of
changes in female sex hormones. 
Although triglyceride levels did not change with peri-
menopause, several variables were related to changes in
triglyceride levels. However, factors related to changes in
triglyceride levels were rather different to those related to
changes in cholesterol levels. Changes in triglyceride levels
were dependent both on body weight and female sex hor-
mones, especially estradiol. In all women, changes in body
weight were the most important variable (r = 0.28, p =
0.005). Changes in triglyceride levels were negatively
associated with changes in estradiol levels in peri-
menopausal women (r = -0.47, p = 0.006) and in all
women with borderline significance (r= -0.19, p= 0.054).
Because the administration of estrogen to post-
menopausal women increases triglyceride levels [17-19],
changes in triglycerides may not be a direct effect of
changes in female sex hormones, but secondary to the
processes associated with the loss of estradiol. We cannot
explain this phenomenon and further studies are neces-
sary.
There are several limitations to the present study. The
number of patients in each group was small and the mean
age was different among the groups. Since changes in lipid
levels were similar between younger premenopausal and
older postmenopausal women, we believe that this differ-
ence did not significantly influence the results. This study
enrolled women who were relatively wealthy and highly
educated, since regular health examinations are expen-
sive. Therefore, the finding may not be applicable to the
general population. In the present study, total and LDL
cholesterol levels were higher in postmenopausal women
transiting from the premenopausal status than in initially
postmenopausal women. We think that this finding
results from the exclusion of postmenopausal hypercho-
lesterolemic women taking lipid-lowering drugs.
The present study demonstrates that total and LDL cho-
lesterol levels increase much more than observed in previ-
ous reports, and this elevation is mainly dependent on
changes in female sex hormones during perimenopause.
Since cardiovascular disease increases after menopause
[1] and hormone replacement therapy is ineffective for
prevention [20], close monitoring and intensive manage-
ment using cholesterol-lowering drugs is necessary for
perimenopausal women. HDL cholesterol levels are not
changed. Although triglyceride levels did not change dur-
ing perimenopause, changes in triglyceride levels were
associated with changes in body weight.Cho EJ, et al. Menopause, Iipids, and related parameters    53
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